0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Visual Observations of an American Patient With Leber Hereditary Optic Neuropathy After Purported Injections of Stem Cells in China FREE

Fawzi Abukhalil, MD; Byron L. Lam, MD; John Guy, MD
[+] Author Affiliations

Author Affiliations: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.


Arch Ophthalmol. 2012;130(4):532-534. doi:10.1001/archophthalmol.2011.1665.
Text Size: A A A
Published online

We describe our clinical observations of a patient with Leber hereditary optic neuropathy and acute vision loss. She received what she was told were umbilical cord blood stem cells by a clinic in Qingdao, China.

A 42-year-old woman noted vision loss in August 2009. Visual acuity was 20/80 (55 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) OD and 20/40+ (71 ETDRS letters) OS. Automated visual field testing revealed bilateral central scotomas, with mean defects of −2.31 dB OD and −0.80 dB OS (Figure 1). The optic nerve heads were swollen with peripapillary telangiectasias characteristic of acute Leber hereditary optic neuropathy. The mean thicknesses of the retinal nerve fiber layers were substantially increased to 130 μm OD and 134 μm OS (Figure 2). The level of serum phosphorylated neurofilament heavy chain, a biomarker of axonal injury, was elevated at 0.29 ng/mL (normal, 0.07 ng/mL). Genetic analysis showed homoplasmy for mutated G11778A ND4 mitochondrial DNA.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Humphrey visual field (30-2 threshold) changes are shown in both eyes at the baseline visit before treatment, 3 months after purported stem cell therapy (the fields show dense central scotomas), 9 months after purported stem cell therapy, and 15 months after purported stem cell therapy.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Fundus photographs. Bilateral optic disc edema was present with peripapillary telangiectasias at the baseline visit before treatment. The optic disc edema had resolved 3 months after purported stem cell therapy. Optic atrophy was prominent 9 months and 15 months after purported stem cell therapy.

Three months later, the patient went to the Chengyang People's Hospital, Qingdao, China, where she received 4 intravenous and 2 intrathecal infusions of what were purported to be umbilical cord blood stem cells according to the schedule listed in the Table; the number of cells infused was not available. Three months after the infusions, visual acuity had worsened to 20/400 (20 ETDRS letters) OD and 20/500 (15 ETDRS letters) OS. Central scotomas were much denser with mean defects of −19.86 dB OD and −21.98 dB OS (Figure 1). Optic disc swelling resolved, with mean retinal nerve fiber layer thicknesses of 97 μm OD and 91 μm OS (Figure 2). The serum phosphorylated neurofilament heavy chain (square root) level had increased to 0.54 ng/mL. Nine months after purported stem cell therapy, visual acuity had worsened further to 20/600 (13 ETDRS letters) OD and 20/800 (4 ETDRS letters) OS. Optic atrophy was prominent with mean retinal nerve fiber layer thicknesses of 67 μm OD and 69 μm OS. Fifteen months after the infusions, the patient's visual acuity stabilized at 20/600 (14 ETDRS letters) OD and 20/700 (8 ETDRS letters) OS. Optic atrophy persisted with mean retinal nerve fiber layer thicknesses of 69 μm OD and 58 μm OS.

Table Graphic Jump LocationTable. Stem Cell Treatment Schedule for 6 Umbilical Cord Blood Stem Cell Injections

While we do not know for certain that this patient received umbilical cord blood stem cells but assume that she did, this is the first peer-reviewed report to our knowledge describing the visual results of treatment with intravenous and intrathecal stem cells in China or elsewhere for vision loss from Leber hereditary optic neuropathy or any other optic neuropathy. The progression of vision loss in our patient with initial optic nerve head swelling followed by optic atrophy is characteristic of the natural history of Leber hereditary optic neuropathy.13 In this well-documented case, intravenous and intrathecal umbilical cord blood stem cell therapy failed to stop the decline in visual function or to prevent optic atrophy. Not withstanding website testimonials, there is no medical evidence that this purported therapy works for optic neuropathies. Therefore, patients and physicians should be cautious in seeking an unproven remedy for a disease that at present has no effective therapy.

Correspondence: Dr Guy, Bascom Palmer Eye Institute, McKnight Research Bldg, 1638 NW 10th Ave, Room 404, Miami, FL 33136 (jguy@med.miami.edu).

Financial Disclosure: None reported.

Sadun AA, Carelli V, Salomao SR,  et al.  Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy.  Am J Ophthalmol. 2003;136(2):231-238
PubMed   |  Link to Article
Seo JH, Hwang JM, Park SS. Comparison of retinal nerve fibre layers between 11778 and 14484 mutations in Leber's hereditary optic neuropathy.  Eye (Lond). 2010;24(1):107-111
PubMed   |  Link to Article
Newman NJ, Biousse V, Newman SA,  et al.  Progression of visual field defects in Leber hereditary optic neuropathy: experience of the LHON Treatment Trial.  Am J Ophthalmol. 2006;141(6):1061-1067
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Humphrey visual field (30-2 threshold) changes are shown in both eyes at the baseline visit before treatment, 3 months after purported stem cell therapy (the fields show dense central scotomas), 9 months after purported stem cell therapy, and 15 months after purported stem cell therapy.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Fundus photographs. Bilateral optic disc edema was present with peripapillary telangiectasias at the baseline visit before treatment. The optic disc edema had resolved 3 months after purported stem cell therapy. Optic atrophy was prominent 9 months and 15 months after purported stem cell therapy.

Tables

Table Graphic Jump LocationTable. Stem Cell Treatment Schedule for 6 Umbilical Cord Blood Stem Cell Injections

References

Sadun AA, Carelli V, Salomao SR,  et al.  Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy.  Am J Ophthalmol. 2003;136(2):231-238
PubMed   |  Link to Article
Seo JH, Hwang JM, Park SS. Comparison of retinal nerve fibre layers between 11778 and 14484 mutations in Leber's hereditary optic neuropathy.  Eye (Lond). 2010;24(1):107-111
PubMed   |  Link to Article
Newman NJ, Biousse V, Newman SA,  et al.  Progression of visual field defects in Leber hereditary optic neuropathy: experience of the LHON Treatment Trial.  Am J Ophthalmol. 2006;141(6):1061-1067
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles